BioPharmSignal logoBioPharmSignal

Biotech News

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SOLIGENIX (SNGX)SOLIGENIXEarnings

SNGX (SNGX) appears in the live feed after a catalyst-style update. The headline is surfaced in real time so readers can move from signal to source without leaving the product flow.

The source domain is sngx.com. BioPharmSignal keeps the ticker, timestamp, and source together for faster review before the wider market catches up.

The original release is available below in a new tab so readers can continue into the full source when needed.

Related news

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

AVTXAvalo Therapeutics2026-08-06 11:00 EST

Avalo Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Updates

IMVTImmunovant2026-08-06 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Quarter Ended June 30, 2026

IMVTImmunovant2026-05-20 11:00 EST

Immunovant Provides Corporate Updates and Reports Financial Results for the Fourth Quarter and Fiscal Year Ended March 31, 2026

CUECue Biopharma Inc2026-05-14 20:07 EST

Cue Biopharma Reports First Quarter 2026 Financial Results and Recent Strategic Developments

GPCRStructure Therapeutics2026-08-06 20:05 EST

Structure Therapeutics Reports Second Quarter 2026 Financial Results and Recent Highlights

KNSAKiniksa2026-07-28 11:30 EST

Kiniksa Pharmaceuticals Reports Second Quarter 2026 Financial Results and Recent Portfolio Execution

HCWBHCW Biologics2026-05-14 20:25 EST

HCW Biologics Reports First Quarter 2026 Business Highlights and Financial Results

XFORX4 Pharmaceuticals2026-08-06 20:15 EST

X4 Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Corporate Update

ALECAlector2026-08-06 20:05 EST

Alector Reports Second Quarter 2026 Financial Results and Provides Business Update

View all latest news

SOLIGENIX

Rare-Disease Biopharmaceutical Company Soligenix develops therapies for rare diseases with substantial unmet need. Its pipeline has included oncology, inflammatory-disease and biodefense programs. HyBryte HyBryte is a synthetic hypericin photodynamic therapy developed for cutaneous T-cell lymphoma. Its confirmatory Phase 3 FLASH2 study...

Recent company news

SNGXSOLIGENIX2026-08-07 11:30 EST

Soligenix Announces Recent Updates and Second Quarter 2026 Financial Results

SNGXSOLIGENIX2026-06-08 11:30 EST

Soligenix Applying for Vaccine Development Funding for Bundibugyo Ebola Vaccine

SNGXSOLIGENIX2026-05-26 11:30 EST

Suitability of Vaccine Platform for Bundibugyo Virus, Cause of the Ebola Outbreak in Congo

SNGXSOLIGENIX2026-05-08 11:30 EST

Soligenix Announces Recent Updates and First Quarter 2026 Financial Results

SNGXSOLIGENIX2026-04-28 11:30 EST

Soligenix Announces Interim Results from the Phase 3 FLASH2 Trial Evaluating HyBryte™ in Treatment of Cutaneous T-Cell Lymphoma

Stock data

Close
0.38 USD
Market cap
11.1M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States